• linkedin
  • Increase Font
  • Sharebar

    A promising target for immunotherapy?


    Bladder cancer tumors with a basal phenotype in patients who have not received neoadjuvant chemotherapy are high risk and aggressive, but they respond favorably to neoadjuvant chemotherapy, leading to increased overall survival.



    Continue to the next page for more take-home messages.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available